Robert A Burger

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Experience with bevacizumab in the management of epithelial ovarian cancer
    Robert A Burger
    University of California, Irvine Medical Center, Irvine, Orange, CA 92868, USA
    J Clin Oncol 25:2902-8. 2007
  2. ncbi request reprint Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study
    Robert A Burger
    University of California, Irvine Medical Center, Building 56, Room 264, 101 The City Dr, Orange, CA 92868, USA
    J Clin Oncol 25:5165-71. 2007
  3. pmc Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer
    Ernest S Han
    University of California Irvine, Orange, CA, USA
    Gynecol Oncol 119:484-90. 2010
  4. doi request reprint A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer
    Troy A Gatcliffe
    Department of Ob Gyn, Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA
    Gynecol Oncol 112:85-9. 2009
  5. pmc Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: a Southwest Oncology Group Study
    Leslie M Randall
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA
    Gynecol Oncol 119:417-21. 2010
  6. pmc Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study
    Shu Yuan Liao
    Department of Epidemiology, University of California at Irvine, School of Medicine, Irvine, CA, USA
    Gynecol Oncol 116:452-8. 2010
  7. ncbi request reprint Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma
    Krishnansu S Tewari
    The Division of Gynecologic Oncology, The Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, 101 The City Drive, Orange, CA 92868, USA
    Gynecol Oncol 98:360-8. 2005
  8. pmc Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study
    Leslie M Randall
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA
    Gynecol Oncol 112:583-9. 2009
  9. pmc Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study
    Bradley J Monk
    University of California, Irvine Medical Center, Bldg 56, Room 262, 101 The City Dr, Orange, CA 92868 USA
    J Clin Oncol 27:1069-74. 2009
  10. pmc Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial
    Leslie M Randall
    Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA
    Gynecol Oncol 124:563-8. 2012

Research Grants

Collaborators

Detail Information

Publications35

  1. ncbi request reprint Experience with bevacizumab in the management of epithelial ovarian cancer
    Robert A Burger
    University of California, Irvine Medical Center, Irvine, Orange, CA 92868, USA
    J Clin Oncol 25:2902-8. 2007
    ....
  2. ncbi request reprint Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study
    Robert A Burger
    University of California, Irvine Medical Center, Building 56, Room 264, 101 The City Dr, Orange, CA 92868, USA
    J Clin Oncol 25:5165-71. 2007
    ..We conducted a phase II trial to assess the efficacy and tolerability of single-agent bevacizumab, an anti-VEGF monoclonal antibody...
  3. pmc Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer
    Ernest S Han
    University of California Irvine, Orange, CA, USA
    Gynecol Oncol 119:484-90. 2010
    ..Potential predictive/prognostic angiogenic markers were prospectively examined in a phase II trial of bevacizumab in epithelial ovarian cancer (EOC)/primary peritoneal cancer (PPC)...
  4. doi request reprint A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer
    Troy A Gatcliffe
    Department of Ob Gyn, Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA
    Gynecol Oncol 112:85-9. 2009
    ..The objective of this study was to assess the feasibility of adding weekly topotecan to cisplatin in patients with primary, locally advanced carcinoma of the cervix receiving pelvic irradiation...
  5. pmc Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: a Southwest Oncology Group Study
    Leslie M Randall
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA
    Gynecol Oncol 119:417-21. 2010
    ..To investigate the feasibility of performing a fresh-tissue, in vitro radiation resistance assay (IVRRA) in a cooperative group setting and to assess the association of IVRRA results with clinical outcomes...
  6. pmc Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study
    Shu Yuan Liao
    Department of Epidemiology, University of California at Irvine, School of Medicine, Irvine, CA, USA
    Gynecol Oncol 116:452-8. 2010
    ....
  7. ncbi request reprint Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma
    Krishnansu S Tewari
    The Division of Gynecologic Oncology, The Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, 101 The City Drive, Orange, CA 92868, USA
    Gynecol Oncol 98:360-8. 2005
    ..To compare the in vitro drug resistance profiles of advanced stage primary and recurrent epithelial ovarian cancer specimens using the tritiated thymidine uptake assay...
  8. pmc Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study
    Leslie M Randall
    Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA
    Gynecol Oncol 112:583-9. 2009
    ..To determine whether markers of tumor angiogenesis were associated with progression-free survival (PFS) and overall survival (OS) in women with high-risk, early-stage cervical cancer treated on a phase III trial...
  9. pmc Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study
    Bradley J Monk
    University of California, Irvine Medical Center, Bldg 56, Room 262, 101 The City Dr, Orange, CA 92868 USA
    J Clin Oncol 27:1069-74. 2009
    ..The Gynecologic Oncology Group (GOG) conducted a phase II trial to assess the efficacy and tolerability of bevacizumab, a recombinant humanized anti-vascular endothelial growth factor monoclonal antibody...
  10. pmc Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial
    Leslie M Randall
    Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA
    Gynecol Oncol 124:563-8. 2012
    ....
  11. ncbi request reprint Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma
    Devansu Tewari
    Chao Family Comprehensive Cancer Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine Medical Center, 101 The City Drive, Orange, CA 92868, USA
    Invest New Drugs 22:475-80. 2004
    ....
  12. ncbi request reprint Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer
    Bradley J Monk
    Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, 1012 The City Drive, Orange, CA 92868, USA
    Gynecol Oncol 102:140-4. 2006
    ..We reviewed our experience with BEV in patients with recurrent advanced epithelial ovarian cancer who had failed multiple prior chemotherapeutic regimens...
  13. ncbi request reprint Gene expression profiling of in vitro radiation resistance in cervical carcinoma: a feasibility study
    Devansu Tewari
    Division of Gynecologic Oncology, University of California Irvine Medical Center, 101 The City Drive South, Orange, CA 92868, USA
    Gynecol Oncol 99:84-91. 2005
    ..To determine the feasibility of integrating an in vitro chemo-radiation response assay (IVRRA) with a gene microarray system to investigate the molecular patterns of expression that contribute to radiation resistance in cervical cancer...
  14. ncbi request reprint Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study
    Robert A Burger
    Department of Obstetrics and Gynecology, University of California Irvine Medical Center, Orange, CA, USA
    Cancer 101:106-15. 2004
    ....
  15. ncbi request reprint Development of an in vitro chemo-radiation response assay for cervical carcinoma
    Bradley J Monk
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California, Irvine, Orange, California 92868, USA
    Gynecol Oncol 87:193-9. 2002
    ..To determine if synergistic effects of radiation (RT) and chemotherapy (chemo) on human cervical carcinoma cell lines and fresh tumor explants could be determined using an in vitro assay...
  16. ncbi request reprint In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer
    Noelle Gillette Cloven
    University of California Irvine, Orange, CA 92868, USA
    Gynecol Oncol 92:160-6. 2004
    ..Biomarker profiles (p53, Her-2 neu, and EGFR) were also evaluated to determine if their expression patterns were associated with histology...
  17. ncbi request reprint Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer
    Bradley J Monk
    Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine, Medical Center, 101 The City Drive, Building 56, Room 262, Orange CA 92868, USA
    Gynecol Oncol 96:902-5. 2005
    ..Angiogenesis is pivotal in the development and progression of ovarian cancer and is an ideal candidate for novel treatment approaches...
  18. ncbi request reprint Primary invasive vaginal cancer in the setting of the Mayer-Rokitansky-Kuster-Hauser syndrome
    Devansu S Tewari
    Division of Gynecologic Oncology, Division of Radiation Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, 101 The City Drive, Orange, CA 92868, USA
    Gynecol Oncol 85:384-7. 2002
    ..Primary vaginal cancer constitutes less than 2% of all malignancies of the female genital tract. A report of the first case of the unlikely occurrence of both of these developments in the same patient is presented...
  19. ncbi request reprint Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapy
    Annie Yessaian
    Department of Obstetrics and Gynecology, Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, Orange, CA 92868, USA
    Gynecol Oncol 94:61-6. 2004
    ..To determine the outcome, complications and likelihood of requiring adjuvant therapy of patients with stage IB2 cervical cancer treated with primary radical hysterectomy and lymph node dissection...
  20. ncbi request reprint Treatment of recurrent gynecologic malignancies with iodine-125 permanent interstitial irradiation
    Bradley J Monk
    Division of Gynecologic Oncology, The Chao Family N C I Designated Comprehensive Cancer Center, University of California, Irvine Medical Center, Orange, CA 92868, USA
    Int J Radiat Oncol Biol Phys 52:806-15. 2002
    ..To analyze the outcome of permanent 125I interstitial radiotherapy for unresectable retroperitoneal recurrences of gynecologic malignancies...
  21. ncbi request reprint Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysis
    John K Chan
    Division of Gynecologic Oncology, The Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California 92868, USA
    Cancer 97:568-74. 2003
    ..The purpose of this study was to evaluate the clinical and pathologic factors associated with survival in patients with neuroendocrine (NE) cervical carcinoma...
  22. ncbi request reprint Early stage cervical cancers containing human papillomavirus type 18 DNA have more nodal metastasis and deeper stromal invasion
    Samuel S Im
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, 101 The City Drive, Orange, CA 92868, USA
    Clin Cancer Res 9:4145-50. 2003
    ..To investigate the clinical and pathological factors which might explain the poor prognosis associated with early stage cervical cancers containing human papillomavirus (HPV) type 18 DNA...
  23. ncbi request reprint Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat model
    John K Chan
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Stanford Cancer Center, 300 Pasteur Drive HH333, Stanford, CA 94305 5317, USA
    Cancer Res 65:3243-8. 2005
    ..Thus, EGFR blockade may ultimately prove to be a useful therapeutic tool in the treatment of cisplatin-sensitive and cisplatin-resistant ovarian cancers...
  24. ncbi request reprint Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
    Stephen A Cannistra
    Beth Israel Deaconess Medical Center, East Campus KS158, 330 Brookline Ave, Boston, MA 02215, USA
    J Clin Oncol 25:5180-6. 2007
    ....
  25. ncbi request reprint Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study
    Joan L Walker
    Department of Obstetrics and Gynecology, University of Oklahoma, PO Box 26901, Oklahoma City, OK 73190, USA
    Gynecol Oncol 100:27-32. 2006
    ..To evaluate reasons for discontinuing intraperitoneal (IP) chemotherapy, and to compare characteristics of patients who did versus did not successfully complete six cycles of IP chemotherapy...
  26. ncbi request reprint Phase II evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: a gynecologic oncology group study
    Jeffrey M Fowler
    Division of Gynecologic Oncology, Ohio State University, Columbus, OH 43210, USA
    Gynecol Oncol 85:311-4. 2002
    ..8%. The duration of the partial response was 15.2 months. CONCLUSION: Oral TMTX has insignificant activity in the treatment of advanced, persistent, and recurrent uterine MMT at the dose and schedule administered...
  27. ncbi request reprint Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study
    Robert F Ozols
    Medical Science Department, Fox Chase Cancer Center, Philadelphia, PA, USA
    J Clin Oncol 21:3194-200. 2003
    ..Thus, we conducted a noninferiority trial of cisplatin and paclitaxel versus carboplatin and paclitaxel in this population...
  28. ncbi request reprint Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study
    Holly H Gallion
    Division of Gynecologic Oncology, Magee Women s Hospital University of Pittsburgh, Pittsburgh, PA, USA
    J Clin Oncol 21:3808-13. 2003
    ..To determine if circadian timed (CT) chemotherapy results in improved response, progression-free survival (PFS), overall survival (OS), and lower toxicity, when compared with standard timed (ST) chemotherapy. Materials and..
  29. ncbi request reprint Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study
    Gini F Fleming
    Gynecologic Oncology Group, Four Penn Center, 1600 JFK Blvd, Suite 1020, Philadelphia, PA 19103, USA
    J Clin Oncol 22:2159-66. 2004
    ..Secondary comparisons included progression-free survival (PFS), response rate (RR), and toxicities...
  30. doi request reprint A new model of ovarian carcinogenesis may influence early detection strategies
    Robert A Burger
    Am J Obstet Gynecol 198:349-50. 2008
  31. ncbi request reprint Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study
    J Tate Thigpen
    Division of Oncology, Department of Medicine, University of Mississippi School of Medicine, Jackson, USA
    J Clin Oncol 22:3902-8. 2004
    ..This trial of stage III, IV, or recurrent disease evaluated whether combining these agents increases response rate (RR) and prolongs progression-free survival (PFS) and overall survival (OS) over doxorubicin alone...
  32. ncbi request reprint Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study
    David R Spriggs
    Division of Solid Tumor Oncology, Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:4466-71. 2007
    ..This study was undertaken to assess if prolonged paclitaxel administration in combination with cisplatin improves overall survival (OS) in epithelial ovarian cancer (EOC)...
  33. ncbi request reprint Phase II trial of pulse dactinomycin as salvage therapy for failed low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study
    Allan Covens
    Division of Gynecology Oncology, University of Toronto, Toronto, Ontario, Canada
    Cancer 107:1280-6. 2006
    ..The purpose of the study was to determine the activity and toxicity of pulse dactinomycin as salvage treatment of patients with low-risk gestational trophoblastic neoplasia (GTN) who failed methotrexate therapy...
  34. ncbi request reprint Intraperitoneal cisplatin and paclitaxel in ovarian cancer
    Deborah K Armstrong
    Johns Hopkins Kimmel Cancer Center, Baltimore, USA
    N Engl J Med 354:34-43. 2006
    ..The Gynecologic Oncology Group conducted a randomized, phase 3 trial that compared intravenous paclitaxel plus cisplatin with intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel in patients with stage III ovarian cancer...
  35. ncbi request reprint Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study
    Benjamin E Greer
    Division of Gynecologic Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Puget Sound Oncology Consortium LF 287, 1100 Fairview Avenue N, Seattle, WA 98109, USA
    Gynecol Oncol 99:71-9. 2005
    ....

Research Grants1

  1. Angiogenesis Targeted Therapeutics of Ovarian Cancer
    Robert Burger; Fiscal Year: 2006
    ..Finally, Dr. Burger will generate a logical sequence of original publications and extramural funding specific to the proposed work. ..